The approval covers the sale of the Renaissance navigation robot for both spinal and neurological procedures.
Mazor Robotics Ltd. (TASE:MZOR) today announced that it has obtained approval from Australia's Therapeutic Goods Administration (TGA) for the import and sale of the company's Renaissance navigation robot for spinal surgery.
Mazor added that the approval covered the sale of the Renaissance navigation robot for both spinal and neurological procedures, on the basis of it's application. It said that, during 2013, it plans to initiate activity sales of the Renaissance system in Australia through a local distributor, LifeHealthcare Distribution pty Ltd., with which it already has an agreement.
The Australian and New Zealand spinal surgical market is estimated at $250 million.
Mazor CEO Ori Hadomi said, "I am pleased at our initial foothold in the Asia-Pacific market. Expanding marketing activity to Australia is a natural follow-on to current activity in other countries in the region, including Japan, China, India, Singapore, South Korea, and Vietnam."